ALX Oncology FY2024 EPS Forecast Raised by Cantor Fitzgerald

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Cantor Fitzgerald boosted their FY2024 earnings per share estimates for shares of ALX Oncology in a note issued to investors on Tuesday, November 12th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($2.69) per share for the year, up from their prior estimate of ($3.08). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.86) per share.

Several other equities research analysts have also issued reports on ALXO. Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a report on Tuesday, August 13th. UBS Group reduced their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Finally, Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and an average price target of $12.50.

ALX Oncology Trading Down 3.0 %

Shares of ALXO stock opened at $1.29 on Friday. The company has a market capitalization of $68.04 million, a PE ratio of -0.45 and a beta of 1.03. ALX Oncology has a 52-week low of $1.25 and a 52-week high of $17.83. The business’s fifty day moving average is $1.70 and its 200 day moving average is $5.68. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Hedge Funds Weigh In On ALX Oncology

Hedge funds have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co purchased a new stake in shares of ALX Oncology during the 1st quarter worth approximately $27,000. EntryPoint Capital LLC bought a new position in ALX Oncology during the first quarter valued at $32,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after buying an additional 5,200 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 2nd quarter valued at about $63,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.